Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:45PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline -- GERN
GlobeNewswire - Fri Apr 11, 3:12PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company"
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Geron Corporation ("Geron" or the "Company"
Hagens Berman Reminds Investors of May 13, 2014, Lead Plaintiff Deadline in Geron Securities Class Action
Business Wire - Wed Apr 09, 12:38PM CDT
Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company"
Top Gainers Technical Data -- Research on First Solar, Ctrip.com Intl., Geron, and Kandi Technologies
PR Newswire - Wed Apr 09, 7:23AM CDT
The US markets saw a positive sentiment on Tuesday, April 08, 2014, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Ctrip.com International Ltd (NASDAQ: CTRP), Geron Corp. (NASDAQ: GERN) and Kandi Technologies Group Inc. (NASDAQ: KNDI). Free technical research on FSLR, CTRP, GERN and KNDI can be downloaded upon signing up at:
Lieff Cabraser Announces Class Action Litigation Against Geron Corporation - GERN
Business Wire - Mon Apr 07, 3:28PM CDT
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Geron Corporation ("Geron" or the "Company"
Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...
Geron Corporation (GERN) Analyst Report: High Potential High Risk Biopharmaceutical Firm Seeking to Advance Novel Innovative Cancer Treatment for myeloid malignancies by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 07, 6:00AM CDT
Geron Corporation (NasdaqGS: GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies. Through internal efforts and potential future strategic partnerships, GERN is positioned to advance the commercialization of Imetelstat in one or more hematologic myeloid malignancies. The discovery and early development of Imetelstat was based on Geron's core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless proliferation.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against GERON CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- GERN
GlobeNewswire - Fri Apr 04, 10:43AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Geron Corporation ("Geron" or the "Company"
ALERT: Rosen Law Firm Reminds Geron Corporation Investors of Important Class Action Deadline -- GERN
GlobeNewswire - Thu Apr 03, 4:48PM CDT
The Rosen Law Firm, P.A. reminds all purchasers of the common stock of Geron Corporation (Nasdaq:GERN) from June 16, 2013 through March 11, 2014, of the important May 13, 2014 lead plaintiff deadline in the class action.
Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...
Geron to Present at the Needham Healthcare Conference
Thomson Reuters ONE - Wed Apr 02, 6:31AM CDT
MENLO PARK, Calif., April 2, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 13th Annual Needham Healthcare Conference in New York. The presentation is scheduled to occur at 8:00 a.m. Eastern Time on Tuesday, April 8th.
Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron Corporation Securities Lawsuit and Investigation
Business Wire - Mon Mar 31, 2:52PM CDT
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company"
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers -- GERN
GlobeNewswire - Fri Mar 28, 12:11PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company"
Geron (GERN) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:09AM CDT
Geron (GERN) Enters Oversold Territory
Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation
PR Newswire - Wed Mar 26, 4:03PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers the securities of Geron Corporation ("Geron" or the "Company"